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Abstract
Cyclic AMP (cAMP) is an important signal transduction second messenger that is commonly used
as a functional mirror on the actions of G protein-coupled receptors that can activate or inhibit
adenylate cyclases. A radioimmunoassay for cAMP with femtomole sensitivity was first reported by
Steiner more than 30 years ago, and there have been several subsequent modifications that have
improved this assay in various ways. Here we describe additional improvement to existing methods
that markedly improve speed and reduce cost without sacrificing sensitivity, and is also adaptable to
analysis of cGMP. The primary antibody is coupled directly to magnetic beads that are then separated
from unbound marker using filtration on microplates. This eliminates the need for a secondary
antibody, and markedly increases throughput. In addition, we report a simple, reproducible, and
inexpensive method to make the radiomarker used for this assay. Although still requiring the use of
radioactivity, the resulting method retains a high degree of accuracy and precision, and is suitable
for low-cost high-throughput screening. Use of aspects of this method can also improve throughput
in other radioimmunoassays.
Introduction
Cyclic AMP (3′,5′-cyclic adenosine monophosphate; cAMP) is a key second messenger
involved in numerous intracellular signaling pathways (Antoni, 2000; McPhee et al., 2005).
Production of cAMP is controlled by the membrane-bound family of adenylate cyclases (ACs)
that convert adenosine triphosphate to cAMP. The activity of most of the ACs is regulated by
heterotrimeric GTP-binding proteins (e.g., Gαs/olf, Gαi/o) that directly interact with the
intracellular region of GPCRs and can both increase or decrease enzyme activity (Hanoune
and Defer, 2001). In addition, phosphodiesterases can catalyze the degradation of cAMP
(Weishaar, 1986).
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The measurement of adenylate cyclase activity can be accomplished using radiometric assays
that follow the incorporation of a radioactive precursor into cAMP (Salomon, 1979; Schulz
and Blum, 1985). More commonly, however, a variety of methods that quantify cAMP have
been used both for assessment of adenylate cyclase activity, as well as for measuring tissue
content of cAMP or breakdown of this second messenger. A major advance for the field was
the development by Steiner et al. (1972) of a radioimmunoassay (RIA) for cAMP that offered
a high degree of sensitivity and specificity that was soon improved by Harper and Brooker
(Harper and Brooker, 1975). Attempts at automating this assay actually led to a commercial
instrument (Brooker et al., 1976), but this proved unwieldy.
More recently, other methods for quantifying cAMP have used different radiometric or reporter
gene strategies (Williams, 2004). Recently developed radiometric assays such as Flashplate
technology (NEN/Perkin Elmer) and scintillation proximity assays (SPA, Amersham
Biosciences) are based on the competition of [125I]-labeled cAMP and analyte cAMP, resulting
in the production of light when the labeled compound is in close proximity to a solid scintillant
surface. These assays are convenient and reproducible, but are often more expensive than
traditional radiometric methods and generally speaking less sensitive. Reporter-gene assays
utilize cell lines expressing reporter enzymes such as luciferase, green fluorescent protein
(GFP), and β-lactamase. Levels of intracellular cAMP are detected via the expression level of
a reporter gene that is modulated by transcription factor binding to upstream cAMP response
elements (CRE). Reporter-gene assay are generally less expensive than the radiometric assays
discussed above, however, they are often plagued by high false-positive hit rates. Several novel,
non-radiometric methods to quantify cAMP also have recently become available. These assays
involve the use of luminescent proximity (ALPHAScreen®) (Ullman et al., 1994), enzyme
complementation technology (DiscoveRx, HitHunter™ EFC), or electrochemiluminescence
(Meso Scale Discovery) to detect receptor-mediated changes in intracellular cAMP. Each
method is readily compatible with automated high throughput screening (HTS), and often
demonstrates a high level of sensitivity, but requires a high degree of instrumentation to
maximize throughput putting it beyond the reach of most academic labs.
For this reason, the RIA (or to a lesser extent, protein binding assays using PKA-enriched
tissue) remains the most widely used technique. There has been a recent report detailing an
improved procedure for this RIA (Post et al., 2000). Indeed, there are commercial kits available
(e.g., Amersham Biosciences) that utilize secondary antibody bound to magnetizable polymer
beads, and are separated by magnetic separation or centrifugation. Using the dopamine D1
receptor as a model system, we now describe improvements to this procedure that decrease the
number of experimental steps, the assay time, and the assay cost, without sacrificing accuracy
or precision. In addition, we describe a rapid method for the routine production of the [125I]-
labeled cAMP derivative that is used as the radiomarker in this RIA.
Experimental procedures and Results
Materials and reagents
Dihydrexidine was synthesized according to procedures previously published (Brewster et al.,
1990). Acetic anhydride, dopamine, IBMX, pargyline, propranolol, SKF38393, and
triethyleneamine, and 2′-O-monosuccinyladenosine 3′:5′ monophosphate tyrosyl methyl ester
(ScAMP-TME) were purchased from Sigma-Aldrich (St. Louis MO). HEPES was obtained
from Research Organics, Inc. (Cleveland OH). Dulbecco’s modified eagle’s media (DMEM),
penicillin/streptomycin, and fetal bovine serum (FBS) were purchased from Gibco/Invitrogen.
UniFilter-96 GF/B RIA filter plates, Microscint™ 20, and Na125I were purchased from Perkin-
Elmer (Waltham, MA, USA). Donkey anti-goat antibody was purchased from Jackson
ImmunoResearch (West Grove, PA, USA). Amine terminated BioMag® beads were purchased
from Polysciences, Inc. (Warrington, PA, USA), and pre-conjugated Biomagnetic Particles
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(BMP) to donkey anti-goat secondary was obtained from Rockland, Inc (Gilbertsville, PA,
USA).
Sample Generation and storage
cAMP is a relatively heat and acid stable compound that does not require special storage. The
following procedure illustrates a common way that samples are generated from a GPCR-based
cellular system, but the assay that follows can be used for almost any matrix.
Cell culture—Human epithelial kidney (HEK-hD1) cells transiently transfected with human
D1 dopamine receptor using pcDNA3.1 vector (Invitrogen) cells were maintained using
Dulbecco’s Modified Eagles’ Medium with 50 U/mL of penicillin, 50 μg/mL of streptomycin
(Gibco), and supplemented with 10% fetal bovine serum at 37°C, 5% CO2. Saturation binding
experiments with the D1-selective antagonist [3H]SCH23390 using membrane homogenates
provided a Bmax of approximately 4.5 pmol/mg protein.
Cell membrane adenylate cyclase assay—Assay buffer was prepared containing 100
mM HEPES, 4 mM MgCl2, 2 mM EDTA, 100 mM NaCl 10 μM pargyline, 500 μM IBMX,
0.1% ascorbic acid, pH 7.4. Drug dilutions were prepared at a range of 10-4 to 10-10 M with
three replicates per drug treatment. Diluted drugs, ATP (2 mM), GTP (5 μM), phosphocreatine
(20 mM), creatine phosphokinase (185 U/tube) and propranolol (100 μM to block endogenous
β1-adrenergic endogenous receptors) were added in a total volume of 100 μL in each well of
a 48-well plate. The reaction was initiated by addition of HEK-hD1 cell membranes. Plates
then were vortexed briefly, and incubated at 30°C for 15 min. The reaction was terminated
with 500 μL 0.1 M HCl, and stored at 4°C. Prior to transferring samples for the RIA, plates
are centrifuged for 5 min at 2,500 g using a RC-3B centrifuge from Sorvall Instruments
(H2000B rotor) to pellet cellular debris. Plates will keep indefinitely at 4°C following the assay.
cAMP Radioimmunoassay
Iodination reaction—The radiomarker 2′-O-[4-monosuccinyladenosine 3′:5′-cyclic
monophosphate-3-[125I]iodotyrosyl methyl ester (hereafter termed ([125I]cAMP-ScTME).was
first reported by Steiner et al. (Steiner et al., 1972) can be purchased commercially. For
laboratories that will run a reasonable number of such assays, it is technically simple and
inexpensive to synthesize this in the laboratory as outlined below. The overall reaction scheme
as outlined by Steiner and coworkers (Steiner et al., 1972) is shown in Figure 1.
The following reagents and buffers are required:
A. 0.5 M phosphate buffer, pH 7.6. We usually make this by titrating 15 mL of 0.5 M
K2HPO4 with ca. 1.5 mL of NaH2PO4 to pH 7.6.
B. 0.05 M phosphate buffer (pH 7.6). This is prepared by adding 10 mL of the 0.5 M
phosphate to 90 mL H2O.
C. Carrier-free Na125I. We usually use 2 or 5 mCi. If more than 5 mCi is used, the amount
of precursor should be increased proportionally,
D. Precursor ScAMP-TME [2′-O-monosuccinyladenosine 3′:5′ monophosphate tyrosyl
methyl ester; Sigma M2257]. From the 1 mg commercial size, we make 1-1.5 mL of
a stock solution containing 0.1 mg/mL of distilled water. Aliquots (50 μL) are added
to microfuge tubes, labeled, and frozen at -20 C. A single aliquot is used for each
radioiodination. The frozen precursor appears stable for several years.
E. Chloramine-T: (20 mg/10 mL 0.05 M PO4).
F. Sodium metabisulfite: (24 mg/10 mL 0.05 M PO4).
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The reaction procedure is as follows. Briefly, 80 μL of the 0.5 M phosphate buffer pH 7.6 is
added directly to the container in which carrier-free Na125I (Perkin Elmer) arrives. We usually
iodinate with 5 mCi, but this can be varied. Then, the whole content of one of the thawed
aliquots of ScAMP-TME (5 μg/50 μL H2O) is added, the cap screwed back on, and the vial
mixed on a vortexer for 15 sec. Following this, Chloramine T (100 μL of 2 mg/mL solution)
is added, and timing begun as the mixture is vortexed. After ∼45 sec, the reaction is terminated
by addition of sodium metabisulfite (200 μL of 2.4 mg/mL solution). [Safety note:
Unreacted 125I is potentially volatile, and a potential health hazard. The use of concentrated
(0.5 M) phosphate buffer insures that the reaction solution does not become acidic, a condition
favoring the liberation of molecular iodine. In addition, this reaction is done in a chemical
hood.]
Purification of iodinated product—It is necessary to separate the monoiodinated cAMP-
ScTME from free iodine, diiodinated cAMP-ScTME and other minor by-products. Although
this can be done using batch chromatography with reverse phase Sep-Pak cartridges
(Oehlenschlager et al., 1990), we have dedicated an archaic isochratic HPLC system and
fraction collector for this purpose. The total reaction volume (∼500 μL) is injected using a
Rheodyne 7125 Injector (500 μL loop). The isocratic separation (0.8 mL/min) uses a C18
reverse phase column (Inertsil ODS 2-5 μm, Metachem Technologies). The column effluent
is collected by a fraction collector (0.5 min samples). As noted above, unreacted 125I is a
potential health hazard, and for the separation, 100 μL of 0.1 M sodium hydroxide is added to
the first ten tubes on the fraction collector to insure that all unreacted iodine remains in the
form of soluble sodium iodide rather than molecular iodine.
The radioactivity is estimated using a hand-held radioactivity detector (or one can count 1 μL
aliquots), and the tubes with the highest radioactivity (usually 3-4 tubes) are pooled together,
diluted with 1.5 volumes of methanol, and then divided into two or more aliquots for storage
at -20°C. Under these conditions, the marker is usable for a minimum of four months, although
there is a significant loss of material due to decay.
Preparation of primary antibody conjugation to amine-terminated beads—The
primary α-3′-5′-cyclic monophosphate antibody was conjugated to BioMag® Amine-
terminated beads (50 mg/mL) as directed by the provided protocol (Polysciences, Inc).
Lyophilized antibody was reconstituted in distilled water to a final concentration of 0.5 mg/
mL, and dialyzed in coupling buffer (0.01 M pyridine in distilled water, pH 6.0), changing the
buffer three-times over a 9 hr period. The beads then were prepared by washing with coupling
buffer, and magnetically separating three times. Glutaraldehyde solution (5% glutaraldehyde
in coupling buffer) was mixed with the BioMag® beads, and reacted for three hours with
rotation. The beads were washed four times with coupling buffer, and antibody was added to
the beads with rotation for 16-24 hrs. Glycine quenching solution (1 M glycine, pH 8.0) was
combined with beads and rotated for 30 min. Primary α-cAMP-beads were mixed a volume of
20 mL of storage buffer (0.01 M Tris, 0.1% NaN3, 0.1% w/v BSA, 0.15 M NaCl, 1 mM EDTA,
pH 7.4), and stored at 4°C. The antibody-bead conjugate was used for up to three months with
no appreciable sign of degradation. Fidelity of the conjugate was assessed by determining the
ratio of binding between two sets of tubes, one containing radiolabeled cAMP bound to primary
antibody and the other containing only radiolabeled cAMP. A ratio of 0.2-0.3 was found to be
ideal while less than 0.2 led to inconsistent replicates.
Radioimmunoassay—cAMP standards (2 nM-500 nM) and sample aliquots (5 μL) were
transferred from the 48-well microplate in which the cAMP formation was performed to 96-
well Skatron plates containing Macrowell tube strips. Sodium acetate buffer (50 mM, pH 6.75)
was added to the sample wells to bring the total volume up to 50 μL. Samples that contain
cAMP outside of the range of the standard curve can be diluted with additional sodium acetate.
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An acetylating mixture of TEA/AA (2:1 ratio) was added (5 μL) to the wells and vortexed.
Acetylation increases assay sensitivity presumably by creating a structure that more closely
resembles the original hapten. 125I-cAMP was then added within 30 minutes of acetylation.
Optimal ranges for radioactivity were determined to be between 280 cpm/μL to 320 cpm/μL
for iodinated 125I-cAMP-scTME. An aliquot (20 μL) of conjugated-primary antibody then was
added to bind labeled and unlabeled cAMP (in 50 mM sodium acetate, 0.1% BSA, pH 4.75).
Plates were incubated overnight at 4°C. Radioimmunoassay reactions were terminated by
filtration with UniFilter-96 plates (Perkin-Elmer) with dH2O. Plates were washed three times
and then dried at 50°C for 1 hour. Microscint™ 20 fluid (50 μL) was added to the wells and
counted on a TopCount NXT (Perkin-Elmer) for 2 min or 2σ = 5%.
Data Analysis
Standard data were fit to a one-site binding competition model using Prism 4 (GraphPad Inc,,
San Diego CA USA). Sample data were fit by interpolation using standard data to obtain fmol
cAMP values. A sigmoidal regression model was used to fit the data to obtain EC50 and
maximal efficacy values over the complete dose range (10-4-10-10 M).
Discussion
It should be underscored that the radiosynthesis of the marker does not require a UV detector
or radioactivity detector to perform this separation, as a lab radioactivity monitor can easily
distinguish the tubes that contain the desired material. Moreover, although we use a dedicated
HPLC system for this work, the separation could be optimized for a SepPak, although the
disadvantage is that it is difficult to verify the separation. This would not save significant time,
but does not require a dedicated “hot” HPLC.
Elimination of secondary antibody allows direct detection
All prior procedures have used secondary antibodies to separate free and antibody-
bound 125I-cAMP-ScTME after the incubation of the analytical samples with the primary
antibody. Techniques have included ammonium sulfate precipitation (Steiner et al., 1972),
charcoal-albumin (Harper and Brooker, 1975), and more recently, polyethylene glycol-assisted
secondary separation of bound and unbound 125I-cAMP (Amersham Biosciences) in which
samples are pelleted by centrifugation, excess fluid in each tube decanted or aspirated, and
bound radioactivity quantified. Subsequent modifications of this method have used secondary
antibody conjugated to magnetic beads for detection of cAMP. All of these procedures are
relatively laborious and we therefore examined whether both cost and time savings might result
from elimination of the use of secondary antibody. We hypothesized that the primary antibody
could be conjugated directly to Biomag® amine-terminated beads (see Materials and
Methods), and then used in a one-step assay. We therefore used the beads prepared as described
above.
To expedite the radioimmunoassay (RIA), we attempted to eliminate the use of secondary
antibody by conjugating anti-succinyl-cAMP antiserum to Biomag® amine-terminated beads
(see Materials and Methods). Following the conjugation of antiserum to Biomag® beads, we
compared the ability of cAMP antiserum to bind cAMP standards. After incubation, the free
radiomarker and that bound to the primary antibody-conjugated BioMag® beads were
separated using a 96-well harvester and UniFilter-96 GF/B plates (1 μm pore size,
PerkinElmer), thus enabling detection of bound radioactivity using a high throughput plate
counter (Perkin-Elmer TopCount NXT). Samples (10 μL) were transferred to Macrowell tube
strips (using a 12-channel electronic pipette) and necessary reagents were added as described
in the Experimental Procedures section. Following overnight incubation with 30 μL of primary
antibody (1:40 dilution), samples were harvested using Filtermate Harvester (Packard) and
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plates were dried for ∼1 h. Scintillation fluid (50 μL) was added to each well, and plates were
counted on a TopCount NXT. Cross-well variation was corrected for following the
manufacturer’s protocol. Not only does this result in useful standard curves, but application to
a well-characterized system (the dopamine D1 receptor) results in EC50 values consistent with
earlier literature. Our results demonstrate that cAMP antiserum conjugated to beads can be
used to separate bound and free 125I-cAMP with the method of separation utilized in this study.
Optimization of cAMP antiserum conditions—To determine optimal conditions for
cAMP antiserum binding, we assessed the ability of the antibody to bind cAMP under variable
assay conditions. cAMP standards were incubated with antiserum volumes of 50 μL and 10
μL (1:40 dilution in 50 mM sodium acetate, pH 6.75) for 2 h at room temperature, and overnight
at 4°C. All assay conditions yielded viable standard curves (Figure 3). As anticipated, the total
amount of cAMP bound was greater for samples incubated with a 50 μL volume of cAMP
antiserum than samples incubated with 10 μL. Incubation overnight resulted in increased levels
of binding for both dilutions compared to the samples incubated for 2 h at room temperature.
These results indicate that antiserum conditions (i.e. dilution, volume, and time of incubation)
can be altered according to individual preference and assay requirements. For future
experiments we chose to use an overnight incubation using 30 μL (per well) of cAMP antiserum
at a 1:40 dilution.
Assay precision and accuracy—To assess the feasibility of our new cAMP method, we
performed an RIA using assay conditions as described by Amersham and our new method.
The adenylate cyclase portion of the assay was conducted as described in the Experimental
Procedures section. Samples were drawn from the same adenylate cyclase plate and cAMP
concentrations were measured using both RIA methods. We determined that the efficacy
(Figure 4) and potency of dopamine and SKF38393 was the same for the old method and our
new method (Figure 4). In light of the fact that some assays are limited by their ability to
distinguish full and partial agonists (Williams, 2004), it is noteworthy that our method easily
detects compounds with partial agonist activity (e.g., SKF38393).
To assess the between-assay reproducibility for our method we pooled the standard deviation
of duplicate samples for twenty assays (Figure 5). The Coefficient of Variation (CV) ranged
from 7-13%, with the CV being 10% or less over a dynamic range of more than two orders of
magnitude. This is an acceptable figure for an assay based on protein binding that uses
radioactivity as its endpoint. It should be noted that a significant portion of the experimental
variance is due to counting error (Mailman and Boyer, 1997;Motulsky, 2007), a factor that can
be decreased by longer counting times if desired. It is known that this assay employs very good
precision, and these data also show that it has good accuracy, both of which could be improved
by longer counting time at the tradeoff of throughput.
Cost issues and alternative technology
In this study we have demonstrated an improved method of cAMP detection that allows for
the quick, accurate measurement of femtomole levels of cAMP. A flowchart of this method is
shown in Figure 6. We have eliminated the need for secondary antibody and time-consuming
separation techniques. By altering the mode of detection and assay format, we have increased
throughput and excluded laborious steps inherent to the previous method. Although our
research focus is on whole-cell and membrane assays of Gαs/OLF, Gαi/o and Gαq/11 coupled
GPCRs, the method is applicable to any measurement of cAMP and can be easily adapted for
cGMP.
The method summarized in Figure 6 significantly reduces the costs required to perform the
assay. Modification of the assay format and method of detection has yielded a substantial
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reduction of the time, labor, and costs, as well as a decrease in reagents used for the previous
method. At the time of submission of this manuscript, [125I]cAMP-ScTME cost $1,517 for 50
μCi (Perkin Elmer; NEX130050). Reagents suitable for dozens of radioiodinations cost less
than $200, and 5 mCi of Na125I can be purchased from Perkin Elmer for $155 yielding a total
cost of finished product for a single iodination of < $100/mCi, several-hundred-fold less than
the commercial cost.
For the overall assay system we estimate our cost to be ca. $0.50/sample, several-fold less
expensive than competing commercial systems. For example, one commercial ELISA assay
costs $310 for a single 96 well assay plate, and also has a sensitivity of at least an order of
magnitude less than the method we describe. Protein binding assays have also been used in the
assay of cAMP for decades ((Brown et al., 1972; Ekins and Brown, 1972). Such protein binding
assays are fast and suitable for high throughput, but are of much lower sensitivity, and also
require preparation of the cAMP binding protein preparation and the use of a long-lived
relatively expensive radioactive marker (i.e., 3H-cAMP). Finally, it should be obvious that this
method could be easily adapted to the radioimmunoassay of cGMP. Indeed, the general
approach used can also improve the throughput of any radioimmunoassay.
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Non-standard abbreviations
AC, Adenylate cyclase; cAMP, cyclic AMP adenosine 3′,5′-cyclic monophosphate; DA,
Dopamine; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; RIA,
Radioimmunoassay; SCH23390, 7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-
benzazepine; SKF38393, 7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
cAMP-ScTME, 2′-O-[4-monosuccinyladenosine 3′:5′-cyclic monophosphate-3-iodotyrosyl
methyl ester.
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Reaction scheme for synthesis of 2′-O-[4-monosuccinyladenosine 3′:5′-cyclic
monophosphate-3-iodotyrosyl methyl ester. Conditions described in Methods (molar excess
of precursor) favor the formation of the monoiodinated product (see Figure 2).
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Chromatogram of radioiodination. [Bottom tracing] shows injection of cAMP-Sc-TME
precursor alone using conditions as described in Methods using 254 nm UV detection. The
solvent front emerges at ∼ 2 min, and the precursor elutes at ∼ 6min. The signal in the solvent
front and a detectable shoulder on the major peak is consistent with the 95% purity estimated
by the supplier. [Top tracing] Actual results from a radioiodination. The monoiodinated product
that is immunologically recognized elutes at ∼28 min, and is the fraction to be collected and
used for the RIA. This fraction contains from 60-70% of the radioactivity in a typical reaction.
The fraction eluting at ∼40 min also contains significant radioactivity (10-20%), and is
presumably the diiodinated form. These two peaks account for ∼80% of the total radioactivity
injected, with the remainder of the radioactivity largely eluting in the solvent front (representing
unreacted iodine or highly polar reaction by-products).
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cAMP standard curves generated under varying assay conditions. Standards were incubated
for 2 hrs. at room temperature with 50 μL (A) and 10 μL (B) primary antibody and overnight
at 4 C [50 μL (C), 10 μL (D)]. Each assay condition yielded a viable standard curve, indicating
that the conditions can be tailored according to the user’s needs.
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Measurement of D1 dopamine receptor-mediated cAMP accumulation utilizing [Left panel]
secondary antibody-PEG assisted RIA method, and [right panel] our new RIA method (primary
antibody conjugated to beads. cAMP production was measured using HEK293 cell membranes
transiently expressing human D1 dopamine receptors. Data are expressed as % maximal cAMP
stimulation caused by dopamine. The curves shown represent mean ± SEM for quadruplicate
determinations of cAMP accumulation from four separate experiments.
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Precision profile demonstrates the Coefficient of Variation as a function of the concentration
of cAMP standards.
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Schematic flowchart of the described method.
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